

2024年12月10日

Zacks Small-Cap Researchによる当社レポートの発表に関するお知らせ

現地時間の12月9日、米国シカゴに本拠を置く投資家向け情報サービス企業 Zacks Small-Cap Research の David Bautz 氏による、当社レポートが発表されましたので、参考情報としてお知らせいたします。

なお、当該レポートは、恐れ入りますが、権利の都合上、英文のままのご案内となりますので、ご了承ください。

【Zacks Small-Cap Research 公式 web サイト】

<https://scr.zacks.com/>

※当該レポートは、本書の下部にありますので、スクロールしてご確認ください。

MediciNova, Inc. (メディシノバ・インク)

東京事務所 IR 担当

E-mail infojapan@medicinova.com

URL <https://medicinova.jp/>

MediciNova, Inc.

(MNOV-NASDAQ)

MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial...

Based on our probability adjusted DCF model that takes into account potential future revenues from MN-166 in ALS and as an MCM; and MN-001 in MASLD, MNOV is valued at \$10.00/share. This model is highly dependent upon continued clinical success of the company's assets and will be adjusted accordingly based upon future clinical results.

Current Price (12/09/24) **\$2.34**
Valuation **\$10.00**

OUTLOOK

On December 5, 2024, MediciNova, Inc. (MNOV) announced a study update and interim analysis from the Phase 2b/3 COMBAT-ALS trial were scheduled to be presented at the 35th International Symposium on ALS/MND. As of Nov. 15, 2024, 217 participants had been enrolled and 183 participants were assigned to either MN-166 or placebo. Positive correlations were seen between the 6-month and 12-month data for the Combined Assessment of Function and Survival (CAFS) scores (0.71), modified CAFS score (0.70), and ASLFRS-R (0.69). The DSMB has recommended that the trial continue as per the protocol. Based on current enrollment, the study is expected to be fully enrolled by mid-2025 and trial results should be reported in 2026.

SUMMARY DATA

52-Week High **\$2.38**
52-Week Low **\$1.13**
One-Year Return (%) **37.65**
Beta **0.84**
Average Daily Volume (sh) **174,635**

Shares Outstanding (mil) **49**
Market Capitalization (\$mil) **\$115**
Short Interest Ratio (days) **N/A**
Institutional Ownership (%) **10**
Insider Ownership (%) **15**

Annual Cash Dividend **\$0.00**
Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates
Sales (%) **N/A**
Earnings Per Share (%) **N/A**
Dividend (%) **N/A**

P/E using TTM EPS **N/A**
P/E using 2024 Estimate **N/A**
P/E using 2025 Estimate **N/A**

Risk Level **High**
Type of Stock **Small-Blend**
Industry **Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	0 A	0 A	1 A	0 A	1 A
2024	0 A	0 A	0 A	0 E	0 E
2025					0 E
2026					0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	-\$0.06 A	-\$0.06 A	-\$0.01 A	-\$0.08 A	-\$0.21 A
2024	-\$0.06 A	-\$0.05 A	-\$0.06 A	-\$0.06 E	-\$0.23 E
2025					-\$0.24 E
2026					-\$0.24 E

WHAT'S NEW

Business Update

Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial

On December 5, 2024, MediciNova, Inc. (MNOV) announced a poster presentation at the 35th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast).

As of November 15, 2024, the trial has enrolled a total of 217 participants and 183 participants have been randomly assigned to treatment with either placebo or MN-166. A pre-defined interim analysis was performed to evaluate the correlation between the 6-month and 12-month data as well as assessing the 12-month double blind phase trial design. A correlation analysis was performed on the (CAFS) scores, modified CAFS scores, and ALSFRS-R scores at six and 12 months.

There was a positive correlation for the 6- and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). The numbers in parentheses represent Spearman Rank Correlation coefficients, which indicates the strength and direction between two sets of data. In practical terms, a coefficient of 0.7 indicates a strong, positive correlation. Positive correlations were also seen for Bulbar score (0.74), fine motor score (0.71), and gross motor score (0.67), however no correlation was seen for respiratory score. Overall, these data support the company's use of a 12-month, double blind trial design. This was further validated by the Data Safety Monitoring Board (DSMB), which reviewed the data and recommended that the trial continue as per protocol.

Based on the current enrollment rate, we estimate that the trial will be fully enrolled by mid-2025, which would lead to release of topline results in 2026.

In addition to the COMBAT-ALS trial, we anticipate the initiation of an Expanded Access Protocol (EAP) trial to evaluate the effect of MN-166 treatment on blood levels of neurofilament light (NfL) in patients with ALS in 2025. That trial is being supported by a \$22 million grant from the National Institutes of Health (NIH) – Neurological Disorders and Stroke (NINDS) with MediciNova providing drug product, regulatory support, and safety monitoring support.

Conclusion

The encouraging update on the Phase 2b/3 COMBAT-ALS trial is a good sign for the company as it moves to finish enrollment in the trial by mid-2025. It's not possible to draw any conclusions regarding the efficacy of MN-166 from the data, however a positive correlation between the 6- and 12-month data is indicative that it will be a robust data set. Assuming the trial can be fully enrolled by mid-2025 we anticipate topline results in 2026. With no changes to our model, our valuation remains at \$10 per share.

PROJECTED FINANCIALS


MediciNova Inc. Income Statement

MediciNova, Inc.	2023 A	Q1 A	Q2 A	Q3 A	Q4 E	2024 E	2025 E	2026 E
MN-166 (ALS)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
MN-166 (GBM)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
MN-001 (NASH)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Grants & Collaborative Revenue	\$1	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Total Revenues	\$1	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Cost of Sales	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>Product Gross Margin</i>	-	-	-	-	-	-	-	-
Research & Development	\$5.7	\$1.8	\$1.6	\$1.9	\$1.5	\$6.8	\$6.0	\$6.3
General & Administrative	\$5.2	\$1.4	\$1.4	\$1.4	\$1.5	\$5.7	\$5.7	\$5.8
Other Expenses	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Operating Income	(\$9.9)	(\$3.1)	(\$3.0)	(\$3.3)	(\$3.0)	(\$12.5)	(\$11.7)	(\$12.1)
<i>Operating Margin</i>	-	-	-	-	-	-	-	-
Non-Operating Expenses (Net)	\$1.3	\$0.4	\$0.4	\$0.5	\$0.0	\$1.3	\$0.0	\$0.0
Pre-Tax Income	(\$8.6)	(\$2.8)	(\$2.6)	(\$2.9)	(\$3.0)	(\$11.2)	(\$11.7)	(\$12.1)
Income Taxes Paid	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>Tax Rate</i>	0%	0%	0%	0%	0%	0%	0%	0%
Net Income	(\$8.6)	(\$2.8)	(\$2.6)	(\$2.9)	(\$3.0)	(\$11.2)	(\$11.7)	(\$12.1)
<i>Net Margin</i>	-	-	-	-	-	-	-	-
Reported EPS	(\$0.17)	(\$0.06)	(\$0.05)	(\$0.06)	(\$0.06)	(\$0.23)	(\$0.24)	(\$0.24)
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
Basic Shares Outstanding	49,046	49,046	49,046	49,046	49,050	49,047	49,200	49,500

Source: Zacks Investment Research, Inc.

David Bautz, PhD

HISTORICAL STOCK PRICE



Source: Zacks Small Cap Research

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.